- Home
- NVCT vs IMAB Comparison
NVCT vs IMAB Comparison
Compare NVCT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- IMAB
- Stock Information
- Founded
- NVCT 2020
- IMAB 2014
- Country
- NVCT United States
- IMAB United States
- Employees
- NVCT N/A
- IMAB N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NVCT Health Care
- IMAB Health Care
- Exchange
- NVCT Nasdaq
- IMAB Nasdaq
- Market Cap
- NVCT 119.4M
- IMAB 83.8M
- IPO Year
- NVCT 2022
- IMAB 2020
- Fundamental
- Price
- NVCT $6.76
- IMAB $1.60
- Analyst Decision
- NVCT Strong Buy
- IMAB Strong Buy
- Analyst Count
- NVCT 1
- IMAB 3
- Target Price
- NVCT $21.00
- IMAB $8.00
- AVG Volume (30 Days)
- NVCT 82.1K
- IMAB 568.7K
- Earning Date
- NVCT 11-06-2024
- IMAB 08-28-2024
- Dividend Yield
- NVCT N/A
- IMAB N/A
- EPS Growth
- NVCT N/A
- IMAB N/A
- EPS
- NVCT N/A
- IMAB N/A
- Revenue
- NVCT N/A
- IMAB $3,492,091.00
- Revenue This Year
- NVCT N/A
- IMAB N/A
- Revenue Next Year
- NVCT N/A
- IMAB N/A
- P/E Ratio
- NVCT N/A
- IMAB N/A
- Revenue Growth
- NVCT N/A
- IMAB N/A
- 52 Week Low
- NVCT $5.85
- IMAB $0.99
- 52 Week High
- NVCT $12.10
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- NVCT 61.30
- IMAB 67.28
- Support Level
- NVCT $6.40
- IMAB $1.25
- Resistance Level
- NVCT $6.65
- IMAB $1.41
- Average True Range (ATR)
- NVCT 0.33
- IMAB 0.13
- MACD
- NVCT 0.07
- IMAB 0.02
- Stochastic Oscillator
- NVCT 90.53
- IMAB 95.92
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).